A Promising Drug for an Inherited Heart Risk Flops, Stunning Doctors
- On Saturday, researchers reported that Novartis drug pelacarsen failed to prevent cardiovascular events in a trial of more than 8,300 patients, despite reducing the genetic heart disease marker Lp by 78%.
- Lp is a genetic risk factor for heart disease affecting roughly 20% of the global population, making it a major target for researchers seeking new cardiovascular prevention strategies.
- Participants received a monthly 70-milligram dose of pelacarsen for a median of 4.7 years, though 20.6% stopped the medication due to adverse effects compared to 7.5% in the placebo group.
- Dr. Steven Nissen of the Cleveland Clinic, who led the trial, called the results 'very disappointing' and an 'extreme surprise,' as experts had expected the drug to reduce cardiovascular risks.
- Despite the trial's failure, experts emphasize that screening for Lp remains valuable, while experimental treatments from Amgen and Eli Lilly advance through development pipelines with results expected by 2029.
27 Articles
27 Articles
The drugs lowered the measured blood values, but did not change what was actually happening in the arteries.
By Brenda Goodman, CNN In the course of scientific discoveries, there are triumphant moments in which researchers present their findings to an absorbed audience who stand up to ovation them.This happened in May in a conference room full of doctors after it was learned that a new drug, Daraxonrasib, almost doubled the survival time of patients with pancreatic cancer.And then there is the reaction that Dr. Steven Nissen expects at the annual confe…
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing - Regional Media News
By Julie Steenhuysen CHICAGO, Nov 7 (Reuters) - An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in clinical trials. Despite a 78% reduction [...]
A promising drug for an inherited heart risk flops, stunning doctors
By Brenda Goodman, CNN (CNN) — In the course of scientific discovery, there are triumphant moments when researchers present their findings to a rapt audience that jumps to its feet for a standing ovation. It happened in a conference room full of doctors in May after they learned a new drug, daraxonrasib, nearly doubled survival
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
